A number of other research analysts have also issued reports on MDWD. Wells Fargo & Company raised their price objective on shares of MediWound to $8.00 and gave the company an “overweight” rating in a report on Wednesday, May 18th. Oppenheimer reiterated an “outperform” rating and set a $7.00 price target on shares of MediWound in a report on Monday, July 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.13.
MediWound Price Performance
MDWD stock opened at $1.67 on Monday. The stock has a market cap of $55.35 million, a price-to-earnings ratio of -3.27 and a beta of 1.14. The company has a 50 day simple moving average of $1.72 and a 200 day simple moving average of $1.99. MediWound has a 1 year low of $1.21 and a 1 year high of $4.11.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Sargent Investment Group LLC lifted its holdings in MediWound by 40.0% in the second quarter. Sargent Investment Group LLC now owns 524,750 shares of the biopharmaceutical company’s stock valued at $966,000 after buying an additional 150,000 shares during the period. Warberg Asset Management LLC bought a new stake in MediWound in the first quarter worth approximately $44,000. Meitav Dash Investments Ltd. lifted its stake in MediWound by 56.1% in the first quarter. Meitav Dash Investments Ltd. now owns 306,538 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 110,129 shares during the period. Finally, We Are One Seven LLC bought a new position in shares of MediWound during the 4th quarter worth approximately $69,000. Institutional investors and hedge funds own 13.58% of the company’s stock.
MediWound Company Profile
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
- Get a free copy of the StockNews.com research report on MediWound (MDWD)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.